Shaojian Lin Changxi Han Xiaohui Lou Zhe Bao Wu
10.3389/fendo.2022.955100
Front Endocrinol (Lausanne)
2022 Aug 2;13:955100.
cabergoline case report hydroxychloroquine novel therapy resistant lactotroph pituitary neuroendocrine tumors
CC BY
https://pubmed.ncbi.nlm.nih.gov/35983516/
Lactotrophs / pathology Neuroendocrine Tumors / complications Neuroendocrine Tumors / drug therapy Neuroendocrine Tumors / surgery Pituitary Neoplasms / complications Pituitary Neoplasms / drug therapy Pituitary Neoplasms / surgery Prolactinoma / complications Prolactinoma / drug therapy Prolactinoma / pathology
Lactotrophs / pathology Neuroendocrine Tumors / complications Neuroendocrine Tumors / drug therapy Neuroendocrine Tumors / surgery Pituitary Neoplasms / complications Pituitary Neoplasms / drug therapy Pituitary Neoplasms / surgery Prolactinoma / complications Prolactinoma / drug therapy Prolactinoma / pathology Case Reports Research Support, Non-U.S. Gov't Adult Cabergoline / therapeutic use Ergolines / therapeutic use Humans Hydroxychloroquine / therapeutic use Male Prolactin Young Adult Ergolines Hydroxychloroquine Prolactin Cabergoline
PMC9379538
35983516
Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report
2022